阿折地平(Azelnidipine) - 药物靶点：L-type calcium channel_在研适应症：高血压_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Azelnidipine (JP17/INN)

+ [5]

靶点

L-type calcium channel

作用机制

L-type calcium channel阻滞剂(L-型电压门控性钙通道家族阻滞剂)

治疗领域

心血管疾病

在研适应症

高血压

非在研适应症-

原研机构

Daiichi Sankyo Co., Ltd.

在研机构

Daiichi Sankyo Co., Ltd.

连云港润众制药有限公司

非在研机构-

最高研发阶段批准上市

首次获批日期

日本 (2003-01-31),

高血压

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C33H34N4O6

InChIKeyZKFQEACEUNWPMT-UHFFFAOYSA-N

CAS号123524-52-7

关联

34

项与阿折地平相关的临床试验

CTRI/2024/08/072999 / RecruitingN/AIIT

Comparison of the Efficacy of 24 Hour BP Control of Azelnidipine, Amlodipine and Cilnidipine in Mild to Moderate Essential Hypertension – a Prospective Multi-centric Parallel Arm Real-world Study (AMCILAZ-EH Study) - AMCILAZ-EH Study

开始日期2024-09-04

申办/合作机构-

CTRI/2024/08/071803 / Not yet recruitingN/AIIT

Post-approval, case control analyses to assess clinical safety and effectiveness of Azelnidipine and Cilnidipine as initial -addon therapy in management of T2DM with HTN - HYDIAZ

开始日期2024-08-13

申办/合作机构-

CTRI/2024/07/071061 / Not yet recruitingN/A

Post-approval, observational study to assess clinical safety and effectiveness of Azelnidipine and Telmisartan in management of Diabetic HTN - TELAZ

开始日期2024-08-02

申办/合作机构

Torrent Pharmaceuticals Ltd.

100 项与阿折地平相关的临床结果

登录后查看更多信息

100 项与阿折地平相关的转化医学

登录后查看更多信息

100 项与阿折地平相关的专利（医药）

登录后查看更多信息

247

项与阿折地平相关的文献（医药）

2024-05-01·Luminescence

Selective detection of azelnidipine in pharmaceuticals via carbon dot mediated spectrofluorimetric method: A green approach

Article

作者: Shah, Shailesh A ; Patil, Pravin O ; Joshi, Shrikant V ; Patel, Paresh N ; Patel, Hetal P ; Kalyankar, Gajanan G ; Maulvi, Furqan A ; Shah, Dinesh R ; Pillai, Arya J ; Merchant, Jesika G ; Lodha, Sandesh R ; Gore, Anil H

AbstractA spectrofluorimetric method using fluorescent carbon dots (CDs) was developed for the selective detection of azelnidipine (AZEL) pharmaceutical in the presence of other drugs. In this study, N‐doped CDs (N‐CDs) were synthesized through a single‐step hydrothermal process, using citric acid and urea as precursor materials. The prepared N‐CDs showed a highly intense blue fluorescence emission at 447 nm, with a photoluminescence quantum yield of ~21.15% and a fluorescence lifetime of 0.47 ns. The N‐CDs showed selective fluorescence quenching in the presence of all three antihypertensive drugs, which was used as a successful detection platform for the analysis of AZEL. The photophysical properties, UV–vis light absorbance, fluorescence emission, and lifetime measurements support the interaction between N‐CDs and AZEL, leading to fluorescence quenching of N‐CDs as a result of ground‐state complex formation followed by a static fluorescence quenching phenomenon. The detection platform showed linearity in the range 10–200 μg/ml (R2 = 0.9837). The developed method was effectively utilized for the quantitative analysis of AZEL in commercially available pharmaceutical tablets, yielding results that closely align with those obtained from the standard method (UV spectroscopy). With a score of 0.76 on the ‘Analytical GREEnness (AGREE)’ scale, the developed analytical method, incorporating 12 distinct green analytical chemistry components, stands out as an important technique for estimating AZEL.

2024-04-01·BMJ Case Reports

Acute quadruple extremity compartment syndrome due to angio-oedema after polypharmacy overdose including olmesartan medoxomil, telmisartan and vildagliptin

Article

作者: Kono, Yumi ; Fujii, Motoki ; Hayashi, Yoshiro ; Takimoto, Kohei

This case report describes a rare manifestation of acute compartment syndrome (ACS) involving all four extremities, precipitated by angio-oedema in a middle-aged woman who consumed an overdose of multiple medications: nifedipine, azelnidipine, amlodipine besylate, olmesartan medoxomil, telmisartan, esaxerenone and vildagliptin. She presented with haemodynamic instability, necessitating intubation. Despite stabilising haemodynamic parameters within 24 hours, she manifested escalating extremity oedema. At 52 hours after ingestion, mottled skin was observed, along with necrotic alterations in the swollen hands and compartment pressures exceeding 30 mm Hg in all extremities. ACS was diagnosed, leading to fasciotomies. The aetiology is postulated to be drug-induced angio-oedema, possibly intensified by the concurrent overdose of olmesartan medoxomil, telmisartan and vildagliptin, each of which has a risk of angio-oedema even at standard dosages. This scenario is a very rare case caused by drug-induced angio-oedema, which underscores the importance of vigilant monitoring to detect ACS in patients with progressing limb oedema.

2024-04-01·Hypertension Research

Effects of vasodilators on beat-to-beat and every fifteen minutes blood pressure variability induced by noradrenaline infusion in rats

Article

作者: Jiang, Danfeng ; Kato, Johji ; Kitamura, Kazuo ; Matsuzaki, Minami ; Ida, Takanori

AbstractIncreased blood pressure variability (BPV) was shown to be associated with cardiovascular morbidities and/or mortalities. There are various types of BPV depending on time intervals of BP measurements, ranging from beat-to-beat to visit-to-visit or year-to-year. We previously found that continuous infusion of noradrenaline (NA) for 14 days increased short-term BPV every 15 min in rats. The aims of this study were to examine (1) whether NA infusion increases very short-term beat-to-beat BPV, (2) the effects of azelnidipine and hydralazine on NA-induced BPV, and (3) whether baroreceptor reflex sensitivity (BRS) is affected by NA or NA plus those vasodilators. Nine-week-old Wistar rats infused subcutaneously with 30 μg/h NA were orally treated with or without 9.7 mg/day azelnidipine or 5.9 mg/day hydralazine over 14 days. BP levels were continuously monitored via abdominal aortic catheter with a telemetry system in an unrestrained condition. Standard deviations (SDs) were used to evaluate beat-to-beat BPV and BPV every 15 min which was obtained by averaging BP levels for 10-s segment at each time point. BRS was determined by a sequence analysis. Continuous NA infusion over 14 days increased average BP, beat-to-beat BPV, and BPV every 15 min, lowering BRS. Comparing the two vasodilators, hydralazine reduced BP elevation by NA; meanwhile, azelnidipine alleviated BPV augmentation, preserving BRS, despite a smaller BP reduction. Thus, NA infusion increased both very short- and short-term BPV concomitantly with impaired BRS, while azelnidipine had an inhibitory effect, possibly independent of BP-lowering, on those types of BPV and impairment of BRS.

100 项与阿折地平相关的药物交易

登录后查看更多信息